TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, today released its RAZR Modular System, the company’s newest LED solution for vertical farmers featuring market-leading efficacies of 2.6 µmol/J under Fluence’s PhysioSpec™ BROAD R3 white spectrum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005453/en/
Fluence’s years of experience collaborating with vertical farmers have proven PhysioSpec™ BROAD R3 is the optimal spectrum choice for crop propagation and full-cycle cultivation for a multitude of leafy greens, microgreens, herbs and other vegetables. Under Fluence’s BROAD R3 spectrum, the newest RAZR system is 18% more efficient than previous generations. The RAZR Modular System’s mechanical mounting and electrical wiring are also highly configurable and easily integrate into various racking styles. The system’s flexible design makes it uniquely suited for scale in a vertical farming environment.
“Vertical farmers are fueling some of the greatest innovations in modern crop production,” said David Cohen, CEO of Fluence. “By simplifying the food supply chain, vertical farms can deliver fresh, nutritional produce to localized regions. These intricate cultivation facilities typically require custom, multilayer racking systems with specialized LED lighting solutions that can optimize plant development through various growth stages. Our RAZR Modular System not only reduces overall operational expenses through its efficient and configurable fixtures, but also offers a proven spectrum for propagation and vertical cultivation for leafy greens, microgreens, herbs and other vegetables.”
Fluence distributes its RAZR Modular System to vertical farmers directly and through partners such as Ecopromt, a leading greenhouse consultancy. Ecopromt’s cultivation experts have designed a fully integrated cart system featuring the RAZR Modular System as well as a proprietary irrigation system. Ecopromt’s integrated cart system has been installed in multiple vertical farms throughout Europe and the U.S.
“Our team has been designing, developing and growing under the most advanced cart systems for vertical farming for nearly a decade,” said Tom Jönsson, head of sales for Ecopromt. “Ecopromt’s fully integrated system is easy to install and built to scale as a vertical farm grows. Combined with our irrigation system and configurable design, RAZR’s modular capabilities provide homogenous light distribution across crops, enabling growers to produce consistent, high-quality plants under some of the industry’s most efficient lighting technology.”
Based in Brooklyn, New York, aquaponic vertical farm Upward Farms leverages Fluence’s RAZR Modular System to optimize growth cycles for several microgreen and baby green variants through different stages of cultivation.
“The RAZR system is flexible, efficient and powerful, which allowed us to quickly and seamlessly integrate it into our grow stacks,” said Ben Silverman, CTO of Upward Farms. “RAZR’s modular nature allows us to tailor the lights to our system while increasing efficiency and reducing grow time.”
For more information about the RAZR Modular System and Fluence’s extended portfolio of LED solutions, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
About Upward Farms
Upward Farms is a USDA-Certified Organic aquaponic vertical farm located in Brooklyn, NY. Upward Farms uses a breakthrough approach that marries modern vertical farming with the ancient practice of aquaponics. This method utilizes fish to fertilize crops in a complete ecosystem that relies on the naturally occurring microbiome, which is the superpower that has sustained life for millions of years. Upward Farms is dedicated to healing the broken food system & reconnecting eaters with flavorful, nutritious, local food. To learn more about Upward Farms, visit www.eatupwardfarms.com .
About Ecopromt
Ecopromt is a family-owned business that works in the horticulture sector, specialized in fresh herbs but also focuses on research and development on other crops. Ecopromt offers consultation on growing and technical advice, with a business strategy of combining biology, chemistry and automation so that growers around the world can get more effective with their crops. Ecopromt with its main office in Sweden is an official reseller of Fluence by OSRAM lights and manufacturer of our own integrated cart systems. Ecopromt also have a branch office in Harrisonburg, Virginia where we offer similar services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005453/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
